Aeterna Zentaris Inc. (NASDAQ:AEZS)‘s stock had its “buy” rating reiterated by Canaccord Genuity in a report issued on Friday. They presently have a $7.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $9.00. Canaccord Genuity’s price objective would indicate a potential upside of 117.39% from the company’s current price.

A number of other equities analysts have also weighed in on the stock. Maxim Group reiterated a “buy” rating and issued a $10.00 price target (down from $11.00) on shares of Aeterna Zentaris in a research report on Thursday, November 10th. Zacks Investment Research lowered shares of Aeterna Zentaris from a “buy” rating to a “hold” rating in a research report on Tuesday, October 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of Aeterna Zentaris in a research report on Thursday, August 11th.

Aeterna Zentaris (NASDAQ:AEZS) opened at 3.45 on Friday. Aeterna Zentaris has a 52-week low of $2.60 and a 52-week high of $15.70. The stock’s market cap is $34.29 million. The firm has a 50 day moving average of $3.77 and a 200-day moving average of $3.57.

About Aeterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

5 Day Chart for NASDAQ:AEZS

Receive News & Stock Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related stocks with our FREE daily email newsletter.